EOAD‐Signature Atrophy Predicts Progression to Dementia in Patients with Early‐onset MCI due to Alzheimer’s Disease
These findings point to the role of EOAD MRI signature as an imaging biomarker to guide prognostication for patients with EOAD and their families and to inform the design of clinical trials.
Authors
- Alexandra Touroutoglou (ORCID: https://orcid.org/0000-0001-9679-2433)
- Michael Brickhouse
- T. Foroud
- Renaud La Joie (ORCID: https://orcid.org/0000-0003-2581-8100)
- Thiago Paranhos (ORCID: https://orcid.org/0000-0001-6489-1955)
- Jeffrey L. Dage (ORCID: https://orcid.org/0000-0002-2192-1699)
- Maria Carrillo
- Kelly Nudelman (ORCID: https://orcid.org/0000-0003-4040-1717)
- Yuta Katsumi (ORCID: https://orcid.org/0000-0003-0413-747X)
- Ani Eloyan (ORCID: https://orcid.org/0000-0002-8110-7680)
- Ryan Eckbo
- Alexander Zaitsev
- Anna Du
- Liana G. Apostolova
- Gil D. Rabinovici
- Brad C. Dickerson
Institutions
- Alzheimer's Association (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_109979
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00